Previous 10 | Next 10 |
2023-05-01 12:41:33 ET Urogen Pharma ( NASDAQ: URGN ) rose 8% amid takeover speculation for the biotech firm focused on bladder cancer. Urogen ( URGN ) is said to have hired investment bank Centerview Partners after receiving a takeover offer for $17 a share, according...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO ® (mi...
- Fireside Chat May 2, 2023 from 10:00 – 10:30 AM ET - UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at...
2023-03-29 12:56:48 ET Gainers: Bird Global ( BRDS ) +44% . Toro Corp ( TORO ) +38% . RenovoRx ( RNXT ) +29% . Arcturus Therapeutics ARCT +26% . Tempest Therapeutics ( TPST ) +26% . Brainstorm Cell Therapeutics ( BCLI ) ...
2023-03-16 15:51:04 ET UroGen Pharma Ltd. (URGN) Q4 2022 Earnings Conference Call March 16, 2023 10:00 AM ET Company Participants Vincent Perrone – Head-Investor Relations Liz Barrett – President and Chief Executive Officer Mark Schoenberg – ...
2023-03-16 08:03:30 ET UroGen Pharma press release ( NASDAQ: URGN ): Q4 GAAP EPS of -$1.22 misses by $0.14 . Revenue of $18.09M (+11.9% Y/Y) misses by $0.42M . For further details see: UroGen Pharma GAAP EPS of -$1.22 misses by $0.14, revenue of $18.09M m...
Reported JELMYTO® full year 2022 net product revenues of $64.4 million, an increase of 34% from full year 2021 Completed enrollment of the ENVISION Phase 3 pivotal clinical trial for UGN-102 for LG-IR-NMIBC Topline data readout from ATLAS clinical study and Complete Response ...
Conference Call and Webcast Scheduled for Thursday, March 16, 2023, at 10:00 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourt...
UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 7 new employees in connection with their ente...
--In a Small Feasibility Study, UGN-102 Achieves a Complete Response in 75% (6 of 8) Patients --UGN-102 is Being Studied in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commerciali...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...